ArticleJournal of the National Cancer Institute2026
Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundThe constituents of tobacco smoke that specifically contribute to lung cancer risk have yet to be fully identified. We evaluated associations between biomarkers of potentially harmful constituents-polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, nicotine, and volatile organic compounds-and lung cancer incidence among US women.
methodsIn a case-cohort study nested within the Sister Study (women aged 35-74 years at baseline, enrolled 2003-2009), data were obtained for a random subcohort and all remaining incident lung cancers through September 2017 (median follow-up = 9.6 years), stratified by race and ethnicity (Hispanic, non-Hispanic Black, non-Hispanic White, others) and smoking status (current, former, never). The analytic sample included 356 cases and 433 noncases. We quantified 30 biomarkers in baseline urine samples and calculated hazard ratios (HRs) for associations between 1-unit increase in biomarker concentrations (log-scale) and lung cancer incidence using weighted Cox regression models adjusted for urinary creatinine and demographic, health, and lifestyle factors.
resultsAmong women who were currently smoking at enrollment, positive associations were observed for biomarkers of polycyclic aromatic hydrocarbons (naphthalene, phenanthrene, pyrene, fluorene; HRs = 1.4-5.3), tobacco-specific nitrosamines (particularly 4-[methylnitrosamino]-1-[3-pyridyl]-1-butanone [nicotine-derived nitrosamine ketone]; HRs = 1.3-2.2), and volatile organic compounds (xylene, acrylamide, acrylonitrile, 1,2-dibromoethane and/or vinyl-chloride and/or ethylene-oxide and/or acrylonitrile, acrolein, styrene and/or ethylbenzene, benzene, dimethylformamide and/or methylisocyanate, 1,3-butadiene, crotonaldehyde, isoprene; HRs = 1.6-4.4). Associations with biomarkers of most polycyclic aromatic hydrocarbons, nicotine-derived nitrosamine ketone, xylene, and dimethylformamide and/or methylisocyanate remained after additional adjustment for smoking frequency, duration, and nicotine metabolites. In women who did not smoke, positive associations were observed for styrene and/or ethylbenzene and dimethylformamide and/or methylisocyanate biomarkers.
conclusionExposure to polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, and several volatile organic compounds through tobacco smoking were associated with increased lung cancer risk among women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.